Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia.
New antibody-based targeted drugs show promise for acute myeloid leukemia, offering hope for patients with limited treatment options beyond standard chemotherapy.
This review surveys antibody-drug conjugates under development for acute myeloid leukemia, covering current clinical trials and design innovations. It maps the evolving ADC landscape for a disease with limited targeted therapy options.
What the study was
- Study design
- Narrative review
- Population
- AML patients
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Frontiers in Bioscience (Elite Edition)
Why it surfaced
ADC pipeline review for AML. Standard review in lower-impact venue.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.